Status:

WITHDRAWN

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Conditions:

Prostate Adenocarcinoma

Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

This phase II trial studies how well focal radiation therapy with stereotactic body radiation therapy (SBRT) or high-dose rate (HDR) brachytherapy works in treating patients with low or intermediate-r...

Detailed Description

PRIMARY OBJECTIVES: I. Evaluate biochemical progression free survival (bPFS) using the Phoenix definition. II. Changes in quality of life. IIa. Prostate-Quality of Life (PR-QOL). IIb. Expanded Prost...

Eligibility Criteria

Inclusion

  • Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy and with the following low/intermediate-risk features:
  • cT1c - T2b
  • PSA =\< 15
  • \< 50% cores positive
  • Gleason score (GS) =\< 7 (3+4 and 4+3 included)
  • Multiparametric magnetic resonance imaging (MRI) (mp-MRI) confirmed lesion(s) with only one lobe involvement of the prostate
  • Unilateral disease on systematic biopsy
  • No distant or locally advanced disease on standard staging exams as indicated
  • Bone scan and abdominopelvic computed tomography (CT)/MRI OR
  • Prostate specific membrane antigen (PSMA) positron emission tomography (PET)
  • Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0/1 within 60 days prior to enrollment

Exclusion

  • Gleason score \>= 8
  • Gross extracapsular extension
  • Seminal vesicle invasion
  • Radiographic nodal or distant metastatic disease
  • Androgen deprivation therapy within 90 days of enrollment
  • Lesion(s) comprising \> 40% of total prostate volume
  • Lesion \< 0.5 cm from urethra
  • Prior radical prostatectomy
  • Prior radiotherapy to the pelvis

Key Trial Info

Start Date :

April 3 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 3 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04399824

Start Date

April 3 2020

End Date

April 3 2020

Last Update

November 6 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States, 90095